Literature DB >> 22490152

[Phenotypic differences of stroma cells in benign and malignant human prostate tissues].

Hui Zhou1, Hong-bin Sun, Wen-bin Huang, Zheng Xu, Jiang-hao Su, Jia-geng Zhu, Rui-peng Jia, Jun Liu.   

Abstract

OBJECTIVE: To analyze the stroma changes of benign and malignant human prostate tissues.
METHODS: For the identification of stroma cells phenotype in human prostate cancer and benign prostate hyperplasia tissues, Masson method and immunohistochemical analysis of α-smooth muscle actin (α-SMA), desmin, and vimentin were performed. The relative volume of intratumor stroma (0%, Grade 0; 1% - 33%, Grade 1; 34% - 66%, Grade 2; 67% - 100%, Grade 3) were quantified and analyzed in local and advanced prostate cancer tissues.
RESULTS: Stroma myofibroblasts in prostate cancer were stained green by Masson staining and showed a co-expression of α-SMA and vimentin without an expression of desmin. It was significantly different from smooth muscle cells in benign prostate hyperplasia stained red and co-expressing a-SMA and desmin. Statistical analysis showed that high stroma volume (Grade 2/3) in advanced prostate cancer were significantly higher than that in an early stage of prostate cancer (83% vs 55%, P < 0.05).
CONCLUSION: Significant phenotypic differences of stroma cells existed in benign and malignant human prostate tissues. A high expression of myofibroblasts in advanced prostate cancer may play an important role in cancer progression. And its clinical significance should raise a high alert.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22490152

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  2 in total

1.  Maturation of the developing human fetal prostate in a rodent xenograft model.

Authors:  Camelia M Saffarini; Elizabeth V McDonnell; Ali Amin; Daniel J Spade; Susan M Huse; Stefan Kostadinov; Susan J Hall; Kim Boekelheide
Journal:  Prostate       Date:  2013-08-30       Impact factor: 4.104

2.  Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy.

Authors:  Jian-Ping Wu; Wen-Bin Huang; Hui Zhou; Lu-Wei Xu; Jian-Hua Zhao; Jia-Gen Zhu; Jiang-Hao Su; Hong-Bin Sun
Journal:  Asian J Androl       Date:  2014 Sep-Oct       Impact factor: 3.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.